The rising share price is presumably linked to the ongoing development of AD-214 and the progression into the clinic. However, it is difficult not to view proceedings through a COVID-19 lens. So what do we see !
It would appear that up to 20% of people contracting the virus develop Acute Respiratory Distress Syndrome. ARDS is a precursor to pulmonary fibrosis. The great pandemic of our time will be followed by the great respiratory medical emergency of our time. At some stage, government, the scientific and medical community and the pharmaceutical industry will shift gears from vaccines to innovative treatments for ARDS and treatments for IPF.
The timeliness of AdAlta's advance into the clinic will not go unnoticed. Look at the number of companies developing vaccines - its a frenzy of activity. Developing new treatments for IPF will take years of painstaking research once a target is found before the journey into the clinic can even begin. Buying or licencing a promising clinical therapy for IPF will soon be top of the list.
1AD Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)